Maravai LifeSciences Holdings, Inc. Stock price

Equities

MRVI

US56600D1072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:51:44 2024-03-28 pm EDT 5-day change 1st Jan Change
8.695 USD +1.34% Intraday chart for Maravai LifeSciences Holdings, Inc. +5.88% +31.91%
Sales 2024 * 273M Sales 2025 * 301M Capitalization 1.14B
Net income 2024 * -6M Net income 2025 * 4M EV / Sales 2024 * 4.14 x
Net cash position 2024 * 7.67M Net cash position 2025 * 83.36M EV / Sales 2025 * 3.49 x
P/E ratio 2024 *
-194 x
P/E ratio 2025 *
668 x
Employees 650
Yield 2024 *
-
Yield 2025 *
-
Free-Float 43.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.88%
1 week+4.76%
Current month+11.00%
1 month+3.87%
3 months+28.83%
6 months-12.09%
Current year+30.99%
More quotes
1 week
7.98
Extreme 7.98
8.87
1 month
6.96
Extreme 6.96
8.87
Current year
5.05
Extreme 5.045
8.87
1 year
4.52
Extreme 4.52
16.62
3 years
4.52
Extreme 4.52
63.55
5 years
4.52
Extreme 4.52
63.55
10 years
4.52
Extreme 4.52
63.55
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 22-09-29
Founder 66 14-02-28
Director of Finance/CFO 53 17-04-30
Members of the board TitleAgeSince
Director/Board Member 57 16-02-29
Director/Board Member 48 16-02-29
Director/Board Member 60 19-12-31
More insiders
Date Price Change Volume
24-03-28 8.64 +0.70% 968 400
24-03-27 8.58 +2.88% 1,855,942
24-03-26 8.34 -1.77% 1,801,098
24-03-25 8.49 -3.08% 2,080,405
24-03-22 8.76 +7.35% 3,569,837

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The Company's segments include Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of modified nucleic acid products to support the needs of customers? research, therapeutic and vaccine programs. This segment also provides research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. It provides products that support its customers? needs from discovery through commercialization of their vaccines, therapeutic agents and in vitro diagnostic products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
8.58 USD
Average target price
9.163 USD
Spread / Average Target
+6.79%
Consensus
  1. Stock
  2. Equities
  3. Stock Maravai LifeSciences Holdings, Inc. - Nasdaq